In acute lymphoblasticleukemia (ALL), hypermethylation of theasparagine synthetase (ASNS) gene promoter, leading to low levelsof ASNS in tumor cells, is recognized as a prognostic biomarker, and l-asparaginase-based treatments (e.g., Asparlas) are frequentlyadministered to these patients. This evidence concerns the gene ASPG and neoplasm.